Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®) develops and commercializes proprietary biological and technological solutions for human health and wellbeing. We manufacture a wide range of critical biological materials for the global diagnostics industry, notably antigens used in immunoassays and Quality Assessment and Proficiency (QAPs™) testing products. Microbix’s business of producing high quality viral and bacterial preparations are the result of nearly three decades of experience in the field, including strain selection, reliable and efficient organism culture at scale, purification and methods of inactivation. As a result of Microbix’s expertise, its products have received widespread and longstanding customer acceptance, with continuing growth in demand. Microbix’s current catalogue of biological preparations covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually-transmitted and insect-borne diseases. The company also applies its biological expertise to develop other innovative and proprietary technologies and products. Its development project pipeline currently includes Kinlytic® Urokinase, a biologic thrombolytic drug used to treat blood clots.

Check out their latest news here.